Incidence and Burden of the Myelodysplastic Syndromes
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Hematology".
Deadline for manuscript submissions: closed (30 June 2019) | Viewed by 144
Special Issue Editor
2. Department of Medicine, Weill Cornell Medical College, New York, NY, USA
Interests: Myelodysplastic Syndrome (MDS); Allogeneic stem cell transplantation (Allo-HCT); post-transplant maintenance treatment; risk stratification pre-transplant; molecular mutations in MDS
Special Issue Information
Dear Colleagues,
Allogeneic stem cell transplantation (allo-HCT) remains the only curative treatment for patients with myelodysplastic syndrome. The introduction of reduced intensity conditioning regimens (RIC) as well as improved donor selection and improved supportive care resulted in better transplant outcomes. However, a recent analysis reported that only about 35% of patients eligible for allo-HCT undergo this curative treatment. The most common reason for not undergoing transplant was mortality related directed to MDS, suggesting delays in referrals for transplant consultation. In this special issue we will focus on recent advances in risk stratification of MDS including molecular data that has emerged in the past decade. We will also discuss new treatment for MDS, asses the role of immunotherapy in treating MDS as well as advances in transplant and post-transplant care at time of relapse and strategies to prevent relapse.
Dr. Roni Tamari
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Myelodysplastic syndrome (MDS)
- Allogenic stem cell
- Transplantation (allo-HCT)
- Disease risk stratification
- Post-transplant maintenance
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
